Copyright
©The Author(s) 2020.
World J Clin Cases. Jul 26, 2020; 8(14): 2917-2929
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.2917
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.2917
Figure 6 APEX2 is highly expressed in liver cancer cells, and knockdown of APEX2 could inhibit the cell viability.
A: Normal LO2 liver cells and HepG2, Huh7, SMMC7721 and HCCLM3 liver cancer cell lines were subjected to detect the APEX2 expression by qPCR; B: The two siRNA sequence against APEX2 was transfected in HCCLM3 cells, and qPCR was applied to confirm the efficiency of knockdown; C: The quantitative analysis of the DNA electrophoresis was conducted by Quantity One software; D: The HCCLM3 cells were transfected with siRNA against APEX2 and scramble control. The cell viability was assessed by CCK-8 at different culture times; E: The HCCLM3 cells were knocked down with siRNA against APEX2 and scramble control, and then treated with different concentration of DOX for 24h. CCK-8 assay was applied to examine the cell viability. siRNA: Small interfering RNA; siCon: Scramble control sequence; DOX: Doxorubicin.
- Citation: Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases 2020; 8(14): 2917-2929
- URL: https://www.wjgnet.com/2307-8960/full/v8/i14/2917.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i14.2917